Vertex tests long-term safety of VX-670 for muscle disease
NCT ID NCT06926621
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This study tests the long-term safety and effectiveness of an experimental drug called VX-670 in adults with myotonic dystrophy type 1 (DM1). Participants who completed a previous VX-670 study can join. The drug is given through a vein, and researchers will monitor side effects and how the drug works in the body over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VX-670 (given intravenously)
What this could lead to
If successful, this could support VX-670 as a long-term treatment to control myotonic dystrophy type 1 symptoms.
What could go wrong
This is an early Phase 2 extension study with only 44 participants, so results may not apply broadly. Long-term safety and effectiveness are still unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY TYPE 1 (DM1) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences Montreal
Montreal, Canada
-
Friedrich Baur Institute
München, Germany
-
Hospital Universitario y Politecnico La Fe - Neurology
Valencia, Spain
-
Leonard Wolfson Experimental Neurology Centre CRF
London, United Kingdom
-
Maastricht UMC
Maastricht, Netherlands
-
Montreal Neurological Institute-Hospital
Montreal, Canada
-
Neuroscience Clinical Trials Unit, Alfred Brain
Melbourne, Australia
-
Queen Elizabeth University Hospital - Neurology
Glasgow, United Kingdom
-
Royal Hallamshire Hospital - Neurology
Sheffield, United Kingdom
-
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology
Leuven, Belgium
-
Universite Laval - Neurology
Québec, Canada
-
University of Ottawa
Ottawa, Canada
-
Wesley Research Institute
Auchenflower, Australia